loading

INVITRO INTERNATIONAL FY 2009 SALES REACH HIGHEST LEVEL IN 12 YEARS

InVitro International
Contact: W. Richard Ulmer
17751 Sky Park East, Suite G
(800) 2-INVITRO
Irvine, CA 92614
http://www.invitrointl.com
Irvine, CA January 13, 2010 – Today InVitro International (OTC, Pink Sheets, IVRO) reported FY 2009 sales of $755,513 and net profits of $50,859. These results when compared to FY 2008 were up 8.5% in sales, and 26% lower in profits. IVRO CEO & President, W. Richard Ulmer, summarized the year by saying: “We were very pleased to show a solid sales increase given the conditions of the U.S. and global economies. Such progress, we believe, reflects the increases in non-animal testing in general and more specifically acceptance of our InVitro International offerings. Furthermore, such gains allow us to continue our increased R&D and Regulatory spending. We made good progress in 2009 with our European regulatory submission and acknowledge with much gratitude the contribution made by our partner, ResPharma, in Italy. We remain optimistic regarding both our current and the future acceptance of our now 25 year old company technologies”.

This release may contain “forward-looking statements” as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. These risks and uncertainties include, but are not limited to: acceptance of the Company’s technology by customers or regulatory agencies, changes in market conditions and other competitive factors. Any such forward-looking statements are not guarantees of future performance.



CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS


Three months ended
September 30


Twelve months ended
September 30


2009


2008


2009


2008


Revenues


215,900


213,386


755,513


696,560


Costs and expenses


237,087


200,493


713,082


640,359


Income (loss) from operations


 (21,187)


 12,892 


42,431


56,201


Other income (loss)


2,698


2,310


8,428


11,230


Net profit (loss)


(18,489)


15,203


50,859


67,431


Profit (loss) per common share


(0.001)


0.001


0.003


0.004


Weighted average common
shares outstanding


16,885,803


16,824,809


16,885,083


16,824,809

CONDENSED CONSOLIDATED BALANCE SHEET

 

 

 


September 30, 2009


September 30, 2008


Cash, cash equivalents and marketable securities


360,660


332,665


Other current assets


204,837


201,949


Total current assets


565,497


534,614


Noncurrent assets


52,886


47,814


Total assets


618,383


582,428


Current liabilities


51,965


74,371


Shareholders’ equity


566,418


508,057


Total liabilities and equity


618,383


582,428

Posted on Categories News

Leave a Reply

Your email address will not be published. Required fields are marked *